Brian Pereira resigns from AMAG
This article was originally published in Scrip
In the same week that AMAG Pharmaceuticals' proposed acquisition of Allos Therapeutics fell through costing the company approximately $1.9 million in the third quarter, and $2 million to be recognised in the fourth quarter, Dr Brian Pereira, AMAG's president and CEO, has resigned. He has also resigned from the board of directors but will remain a strategic advisor to the company on some matters, including the ongoing development and regulatory work on its Phase III programme for iron deficiency anaemia. Gary Zieziula, AMAG's chief commercial officer has also left the company. Frank Thomas, the company's CFO, has been promoted to COO and appointed interim president and CEO. AMAG has launched a search for a permanent replacement for Dr Pereira. Additionally, AMAG's board has established a special committee consisting of Michael Narachi, Robert Perez and Dr Lesley Russell to oversee the transition period.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.